Daito Pharmaceutical Co., Ltd.
Q1 Financial Summary for the Fiscal Year Ending May 2027 [Japan GAAP] (Consolidated)
For Q1 of the fiscal year ending May 2027, consolidated revenue was 11,894 million yen, down -8.6% year-over-year, operating income was 712 million yen, ordinary income was 808 million yen, and net income attributable to owners of parent was 700 million yen. The full-year forecast remains unchanged from the previous announcement: full-year revenue 54,000 million yen, operating income 4,000 million yen, and net income 3,000 million yen. The full-year dividend forecast is 45 yen.
Key Figures
- Revenue: 11,894 million yen (YoY -8.6%)
- Operating Income: 712 million yen (YoY -28.7%)
- Net Income Attributable to Owners of Parent: 700 million yen (YoY 0.6%)
AI要約
Performance Overview
Total revenue for the quarter was approximately 11.9 billion yen, down year-over-year, affected by higher raw material costs and inventory valuation losses. Operating income was 712 million yen, ordinary income was 808 million yen, and net income was 700 million yen, indicating a slowdown in profitability. However, the full-year plan remains unchanged from the previously announced figures, with expected revenue of 54,000 million yen, operating income of 4,000 million yen, and net income of 3,000 million yen.
Outlook and Investor Impact
Under the medium-term plan "Daito Transformation Plan 2027," the company is promoting stable supply and production capacity enhancement in the pharmaceutical business. While attention is required regarding rising raw material costs and yen depreciation, supplemental explanatory materials for the financial results have been prepared to clarify future projections. Future performance will depend on recovery in revenue and improvements in cost management, which will determine the achievability of the full-year forecast.
Revenue Trend
Operating Income Trend
Segment Revenue Composition
Margin Analysis
Daito Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
